Latest Breaking News On - ஜோசப் கிம் - Page 12 : comparemela.com

Image/ C. S. Goldsmith, P. Rollin, M. Bowen The Phase 1B clinical trial (LSV-002), ongoing at the Noguchi Memorial Institute for Medical Research in Accra, Ghana, is the first vaccine clinical trial for Lassa fever to be conducted in West Africa, where the infection is endemic. INO-4500 is also the first vaccine candidate for Lassa fever to enter human trials. INOVIO is advancing INO-4500 with full funding from the Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership that leverages funding from public, private, philanthropic, and civil society organizations to support research projects to develop vaccines against emerging infectious diseases. INOVIO previously received a $56 million grant from CEPI in 2018, under which the company is developing vaccine candidates for Lassa fever and Middle East Respiratory Syndrome (MERS). INOVIO and CEPI are committed to making a vaccine available as soon as possible for emergency use as a stockpile product post-Phas

Greater accraJoseph kimMelanie savilleKwadwoa koramNoguchi medical centerNoguchi memorial institute for medical researchCoalition for epidemic preparedness innovationsNoguchi memorial instituteMedical researchWest africaEpidemic preparedness innovationsMiddle east respiratory syndromePrincipal investigatorஅதிகமானது அக்ராஜோசப் கிம்மெலனி ஸாவில்